Beta Bionics, Inc. (NASDAQ:BBNX) Stock Has Average Target Price of $24.00

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $24.00.

Several equities research analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Beta Bionics in a research report on Monday. They issued a “buy” rating and a $30.00 price target on the stock. Bank of America raised their price objective on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. William Blair started coverage on Beta Bionics in a research note on Friday, August 21st. They issued a “market perform” rating on the stock. Finally, Truist Financial boosted their price target on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $16.35 on Friday. Beta Bionics has a 1 year low of $8.80 and a 1 year high of $32.71. The stock has a market cap of $735.59 million, a PE ratio of -9.91 and a beta of 3.39. The business’s fifty day moving average is $19.04 and its 200-day moving average is $15.19.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities research analysts predict that Beta Bionics will post -2.02 earnings per share for the current year.

Insider Activity

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the sale, the director directly owned 19,564 shares of the company’s stock, valued at $449,972. This represents a 24.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 98,472 shares of company stock valued at $1,920,481. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Beta Bionics

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new position in Beta Bionics during the second quarter worth $2,524,000. Bank of America Corp DE bought a new position in Beta Bionics during the second quarter valued at about $8,566,000. Man Group plc bought a new position in Beta Bionics during the second quarter valued at about $419,000. Legal & General Group Plc bought a new position in Beta Bionics during the second quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics in the second quarter worth about $172,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
• Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
• Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
• Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.